Cardiovascular Endocrinology & Metabolism最新文献_第10页

A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA. 针对美国初级保健医生的心血管指南相关建议的重点回顾。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000192

Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton

{"title":"A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA.","authors":"Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton","doi":"10.1097/XCE.0000000000000192","DOIUrl":"10.1097/XCE.0000000000000192","url":null,"abstract":"Primary care physicians in the USA serve the critical role of first contact for undiagnosed or mismanaged pathologies as well as providers of continuous care in multiple communities. Their scope of practice is broad from medication reconciliation to coordinating specialty care and even performing office procedures. Primary care physicians in the USA commonly encounter patients with diabetes and associated comorbidities related to prolonged insulin resistance. Mainly these include heart failure exacerbation or major adverse cardiovascular events. The demanding roles primary care physicians serve may render these providers encumbered to navigate through long, verbose and dynamic guidelines related to managing diabetes and cardiac diabetology sequelae. Our aim is to compose current, prominent evidence-based points from American medical societies such as the American College of Cardiology/American Heart Association and the American Diabetes Association central to lifestyle modifications, antiplatelet therapy, anti-hyperglycemic and SGLT2-inhibitor utilization, hypertension, dyslipidemia, and heart failure screening in a way that is both succinct and valuable to primary care physicians.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228774/pdf/xce-9-36.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. 新型非他汀疗法对心血管糖尿病的系统性影响：以 PCSK9 为例

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-05 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000204

Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton

{"title":"The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.","authors":"Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton","doi":"10.1097/XCE.0000000000000204","DOIUrl":"10.1097/XCE.0000000000000204","url":null,"abstract":"PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modulating lipid metabolism, improve mortality outcomes in cardiovascular disease. These benefits are markedly pronounced in patients with type 2 diabetes mellitus. However, these benefits do not come without associated risk. Multiple trials, studies, and case reports have attempted to explain observed outcomes with PCSK9 expression and administration of PCSK9 inhibitors from multiple perspectives, such as their effects on insulin sensitivity and glucose tolerance, changes in renal physiology, thyroid physiology, vascular tone, intestinal regulation of lipids, and improved cardiovascular function. These agents represent an opportunity for physicians to exercise prudence by using appropriate clinical judgement when managing comorbidities in the hyperglycemic patient, a concept that extends to other novel non-statin drugs.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673769/pdf/xce-9-143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications. COVID-19 心血管并发症发病机制中可能存在的分子和旁分泌作用。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-04-20 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000207

Antoine Fakhry AbdelMassih, David Ramzy, Lauren Nathan, Silvia Aziz, Mirette Ashraf, Nourhan Hatem Youssef, Nouran Hafez, Rana Saeed, Hala Agha

{"title":"Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications.","authors":"Antoine Fakhry AbdelMassih, David Ramzy, Lauren Nathan, Silvia Aziz, Mirette Ashraf, Nourhan Hatem Youssef, Nouran Hafez, Rana Saeed, Hala Agha","doi":"10.1097/XCE.0000000000000207","DOIUrl":"10.1097/XCE.0000000000000207","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) has been declared a pandemic on 11 March 2020 by the WHO. Despite being mainly a respiratory virus, cardiac complications have been described. These range from sudden cardiac death to subtle diastolic dysfunction after recovery from COVID-19. The commonest cardiac presentation to date is acute heart failure resulting from biventricular or left ventricular hypokinesis and elevation of cardiac troponins. It has been shown that COVID-19 downregulates angiotensin-converting enzyme-2, which has protective effects on the endothelium and cardiomyocytes. It has also been proven that COVID-19 induces a state of hypercytokinaemia, some cytokines such as interleukin-1 and interleukin-6 have an injurious effect on the myocardium and endothelium, respectively. Such pathogenic mechanisms might play a crucial role in induction of cardiomyocyte injury and impaired myocardial perfusion probably through coronary endothelial dysfunction. The understanding and linking of such mechanisms might help in tailoring drug repurposing for treatment or prophylaxis of COVID-19 cardiovascular complications.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410028/pdf/xce-9-121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 78-year-old male with inferior ST-segment elevation on electrocardiogram, diabetic ketoacidosis and acute pancreatitis. 78岁男性，心电图下st段抬高，糖尿病酮症酸中毒，急性胰腺炎。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-04-17 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000205

Jamie S Y Ho, Bryan Mui, Ching-Hui Sia, Andie H Djohan, Shao-Feng Mok, Mark Y Chan, Anand A Ambhore

引用次数: 1

Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities. 糖尿病患者心血管疾病的预防和管理：当前的挑战和机遇。

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-04-17 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000199

Dennis Bruemmer, Steven E Nissen

引用次数: 0

Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. 非酒精性脂肪肝：对内分泌专家和心脏病专家的影响。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-03-23 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000197

Gerardo Rodriguez-Araujo

{"title":"Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists.","authors":"Gerardo Rodriguez-Araujo","doi":"10.1097/XCE.0000000000000197","DOIUrl":"10.1097/XCE.0000000000000197","url":null,"abstract":"Type 2 diabetes mellitus is not just a risk factor but a progression factor for a plethora of multi-organ complications, including the liver and the vascular system. The profibrogenic-inflammatory liver disease nonalcoholic steatohepatitis affects patient's mortality and overall cardiovascular and liver-related complications. There is an evident overlap between these diseases; therefore, there are important implications for endocrinologists, cardiologists, and hepatologists when treating these patients. In addition, as newly approved nonalcoholic steatohepatitis pharmacotherapy is expected to be available early this year, clinicians need to be able to identify patients with type 2 diabetes mellitus that are at risk of advanced liver fibrosis to establish adequate and efficient management plans to limit or avoid cardiovascular or liver-related complications. In this review, we summarize the current knowledge in the nonalcoholic steatohepatitis field with potential value for clinicians focusing on the implications of the overlap between type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis, the available diagnostic tools for risk stratification, management pathways, and nonalcoholic steatohepatitis pharmacotherapy, including antidiabetic and cardiovascular drugs that may be beneficial or detrimental to their patients.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410017/pdf/xce-9-096.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiometabolic disease in the older person: prediction and prevention for the generalist physician. 老年人心脏代谢疾病:全科医生的预测和预防。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-02-22 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000193

Alan J Sinclair, Ahmed H Abdelhafiz

引用次数: 16

Effects of aerobic and anaerobic exercise on glucose tolerance in patients with coronary heart disease and type 2 diabetes mellitus. 有氧和无氧运动对冠心病和2型糖尿病患者糖耐量的影响

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-02-21 eCollection Date: 2020-03-01 DOI: 10.1097/XCE.0000000000000188

Bernhard Schwaab, Friderike Kafsack, Edith Markmann, Morten Schütt

{"title":"Effects of aerobic and anaerobic exercise on glucose tolerance in patients with coronary heart disease and type 2 diabetes mellitus.","authors":"Bernhard Schwaab, Friderike Kafsack, Edith Markmann, Morten Schütt","doi":"10.1097/XCE.0000000000000188","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000188","url":null,"abstract":"In patients with coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM), physical activity is strongly advised as nonpharmacological therapy. In general, a moderate aerobic exercise intensity is recommended. It was also proposed, however, that greater intensities tend to yield even greater benefits in HbA1c. Hence, the most appropriate exercise intensity seems not to be established yet. We compared the effect of moderate (aerobic) and vigorous (anaerobic) activity on postprandial plasma glucose.Methods: In 10 consecutive patients (63 ± 12 years, BMI 28.3 ± 2.6 kg/m2, fasting plasma glucose 6.1 ± 1.2 mmol/l), 2-hour plasma glucose was ≥11.1 mmol/l in the oral glucose tolerance test at rest (OGTT-0). Cardiopulmonary exercise test (CPX) was performed until a respiratory exchange ratio (RER) ≥1.20, beeing anaerobic (CPX-1), followed by OGTT-1. A steady-state CPX of 30-minute duration was performed targeting an RER between 0.90 and 0.95, being aerobic (CPX-2), followed by OGTT-2.Results: In CPX-1, maximum exercise intensity (maxIntensity) averaged at 99 ± 30 Watt and peak oxygen consumption (VO2peak) reached 15.9 ± 2.8 ml/min/kg. In CPX-2, aerobic intensity averaged at 29 ± 9 Watt, representing 31% of maxIntensity and 61% of VO2peak. After aerobic exercise, 2-hour plasma glucose was significantly reduced to an average of 9.4 ± 2.3 mmol/l (P < 0.05). Anaerobic exercise did not reduce 2-hour plasma glucose as compared to OGTT-0 (12.6 ± 2.2 vs 12.6 ± 3.9 mmol/l).Conclusion: Aerobic exercise intensity was very low in our patients with CHD and T2DM. Postprandial plasma glucose was reduced only by aerobic exercise. Larger studies on the optimal exercise intensity are needed in this patient cohort.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37682571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11

Acute hyperglycemia and contrast-induced nephropathy in patients with non-ST elevation myocardial infarction. 非st段抬高型心肌梗死患者的急性高血糖和造影剂肾病。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-02-21 eCollection Date: 2020-03-01 DOI: 10.1097/XCE.0000000000000187

Onur Baydar, Alparslan Kilic

{"title":"Acute hyperglycemia and contrast-induced nephropathy in patients with non-ST elevation myocardial infarction.","authors":"Onur Baydar, Alparslan Kilic","doi":"10.1097/XCE.0000000000000187","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000187","url":null,"abstract":"Acute hyperglycemia and contrast-induced nephropathy (CIN) are frequently observed in non-ST elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI), and both are associated with an increased mortality rate. We investigated the possible association between acute hyperglycemia and CIN in patients with NSTEMI undergoing PCI.Materials and methods: We retrospectively enrolled 281(149, 53% men) NSTEMI patients undergoing PCI. For each patient, plasma glucose levels were secreened at hospital admission. Acute hyperglycemia was defined as glucose levels > 198 mg/dl. CIN was defined as an increase in serum creatinine 25% or 0.5 mg/dl from baseline in the first 48-72 hours.Results: Overall, 44 (15.7%) patients had acute hyperglycemia. Patients with acute hyperglycemia had higher incidence of CIN than those without acute hyperglycemia (29.5 vs 5.1%, P < 0.001). Also, in-hospital mortality, length of hospital stay, major bleeding, requirement of mechanical ventilation and dialysis were observed significantly higher in patients with hyperglycemia. Patients were then reallocated to two groups according to the presence or absence of CIN. Overall, 25 cases (8.9%) of CIN were diagnosed. Diabetes mellitus, weight, age, glucose level and estimated glomerular filtration rate (eGFR) were detected as independent risk factors of CIN. Additionally, admission glucose levels were significantly correlated with creatinine levels after PCI, eGFR and contrast volume/eGFR ratio.Conclusion: In NSTEMI patients undergoing primary PCI, acute hyperglycemia may be associated with an increased risk for CIN and in-hospital mortality and morbidity.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000187","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37683415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

A treatment-based algorithm for identification of diabetes type in the National Health and Nutrition Examination Survey. 一种基于治疗方法的国民健康与营养检查调查中糖尿病类型识别算法。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-02-21 eCollection Date: 2020-03-01 DOI: 10.1097/XCE.0000000000000189

Mitra Mosslemi, Hannah L Park, Christine E McLaren, Nathan D Wong

{"title":"A treatment-based algorithm for identification of diabetes type in the National Health and Nutrition Examination Survey.","authors":"Mitra Mosslemi, Hannah L Park, Christine E McLaren, Nathan D Wong","doi":"10.1097/XCE.0000000000000189","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000189","url":null,"abstract":"In epidemiology studies, identification of diabetes type (type 1 vs. type 2) among study participants with diabetes is important; however, conventional diabetes type identification approaches that include age at diabetes diagnosis as an initial criterion introduces biases. Using data from the National Health and Nutrition Examination Survey, we have developed a novel algorithm which does not include age at diagnosis to identify participants with self-reported diagnosed diabetes as having type 1 vs. type 2 diabetes.Methods: A total of 5457 National Health and Nutrition Examination Survey participants between cycles 1999-2000 and 2015-2016 reported that a health professional had diagnosed them as having diabetes at a time other than during pregnancy and had complete information on diabetes-related questions. After developing an algorithm based on information regarding the treatment(s) they received, we classified these participants as having type 1 or type 2 diabetes.Results: The treatment-based algorithm yielded a 6-94% split for type 1 and type 2 diabetes, which is consistent with reports from the Centers for Disease Control and other resources. Moreover, the demographics and clinical characteristics of the assigned type 1 and type 2 cases were consistent with contemporary epidemiologic findings.Conclusion: Applying diabetes treatment information from the National Health and Nutrition Examination Survey, as formulated in our treatment-based algorithm, may better identify type 1 and type 2 diabetes cases and thus prevent the specific biases imposed by conventional approaches which include the age of diabetes diagnosis as an initial criterion for diabetes type classification.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37682572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11